Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group

Journal of Clinical Oncology

Volumn 21, Issue 16, 2003, Pages 3025-3034

  Gridelli, Cesare ^a   Gallo, Ciro ^a   Shepherd, Frances A ^a   Illiano, Alfonso ^a   Piantedosi, Francovito ^a   Robbiati, Sergio Federico ^a   Manzione, Luigi ^a   Barbera, Santi ^a   Frontini, Luciano ^a   Veltri, Enzo ^a   Findlay, Brian ^a   Cigolari, Silvio ^a   Myers, Robert ^a   Ianniello, Giovanni P ^a   Gebbia, Vittorio ^a   Gasparini, Giampietro ^a   Fava, Sergio ^a   Hirsh, Vera ^a   Bezjak, Andrea ^a   Seymour, Lesley ^a   Perrone, Francesco ^a   more..

^a Queen's Cancer Research Institute

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; VINBLASTINE;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FATIGUE; FEVER; HEARING DISORDER; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING; CANADA; COMPARATIVE STUDY; FEMALE; ITALY; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; ITALY; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0041912766     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.099     Document Type: Article

References (42)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2:533-543, 2001
2. Non Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised trials. BMJ 311:899-909, 1995
3. Bunn-PA J, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 4:1087-1100, 1998
4. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002
5. Kelly K, Crowley J, Bunn PA, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 19:3210-3218, 2001
6. Herbst RS, Lynch C, Vasconcelles M, et al: Gemcitabine and vinorelbine in patients with advanced lung cancer: Preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol 48:151-159, 2001
7. Gridelli C, Frontini L, Perrone F, et al: Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: A phase II study of three different doses. Br J Cancer 83:707-714, 2000
8. Bajetta E, Chiara Stani S, De Candis D, et al: Gemcitabine plus vinorelbine as first-line chemotherapy in advanced non small cell lung carcinoma: A phase II trial. Cancer 89:763-768, 2000
9. Lilenbaum R, Cano R, Schwartz M, et al: Gemcitabine and vinorelbine in advanced non small cell lung cancer: A phase II study. Cancer 88:557-562, 2000
10. Isokongas OP, Knuttila A, Halme M, et al: Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non small cell lung cancer. Ann Oncol 10:1059-1063, 1999
11. Chen YM, perng RP, Yang KY, et al: A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB-IV) non small cell lung cancer. Chest 117:1583-1589, 2000
12. Laack E, Mende T, Benk J, et al: Gemcitabine and vinorelbine as first-line chemotherapy for advanced non small cell lung cancer: A phase II trial. Eur J Cancer 37:583-590, 2001
13. Krajnik G, Mohn-Staudner A, Thaler J, et al: Vinorelbine-gemcitabine in advanced non-small-cell lung cancer: An AASLC phase II trial. Ann Oncol 11:993-998, 2000
14. Palmeri S, Leonardi V, Gebbia V, et al: Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): A multicentre phase II clinical trial. Lung Cancer 34:115-123, 2001
15. Lorusso V, Carpagnano F, Frasci G, et al: Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 18:405-411, 2000
16. Hirsh V, Langleben A, Ayoub J, et al: Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: A phase II multicenter trial. Cancer 92:830-835, 2001
17. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
18. Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A:635-642, 1994
19. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
20. Pocock SJ: Group sequential methods in the design and analysis of clinical trials. Biometrika 64:191-199, 1977
21. Fayers P, Aaronson N, Bjordal K, et al: EORTC Scoring Manual (ed 2). Brussels, Belgium, Quality of Life Unit, EORTC Data Centre, 1999
22. Armstrong BG, Sloan M: Ordinal regression models for epidemiologic data. Am J Epidemiol 129:191-204, 1989
23. Berridge DM, Whitehead J: Analysis of failure time data with ordinal categories of response. Stat Med 10:1703-1710, 1991
24. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
25. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
26. Cox DR: Regression models and life tables. J Roy Stat Soc B 34:187-220, 1972
27. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
28. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17:3188-3194, 1999
29. Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
30. Berthelot JM, Will BP, Evans WK, et al: Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst 92:1321-1329, 2000
31. Smith IE, O'Brien MER, Talbot DC, et al: Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336-1343, 2001
32. Socinski MA, Schell MJ, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335-1343, 2002
33. Breathnach OS, Freidlin B, Conley B, et al: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 19:1734-1742, 2001
34. Silvestri G, Pritchard R, Welcj HG: Preferences for chemotherapy in patients with advance non-small-cell lung cancer: Descriptive study based on scripted interview. BMJ 317:771-775, 1998
35. Rodriguez J, Pawel J, Pluzanska A, et al: A multicenter randomized phase III study of docetaxel + cisplatin and docetaxel + carboplatin vs vinorelbine + cisplatin in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 20:314a, 2001 (abstr 1252)
36. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European Multicenter Trial including 612 patients. J Clin Oncol 12:360-367, 1994
37. Georgulias V, Papadakis E, Alexopoulos A, et al: Platinum-based and non-platinum based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial. Lancet 357:1478-1484, 2001.
38. [Correspondence in Lancet 358:1271-1272, 2001.]
39. Van Meerbeeck JP, Smit EF, Lianes P, et al: A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 20:308a, 2001 (abstr 1228)
40. Alberola V, Camps C, Provencia M, et al: Cisplatin/gemcitabine vs cisplatin/gemcitabine/vinorelbine vs sequential doublets of gemcitabine/ vinorelbine followed by ifosfamide/vinorelbine in advanced non-small-cell lung cancer: Results of a Spanish lung cancer group phase III trial. Proc Am Soc Clin Oncol 20:308a, 2001 (abstr 1229)
41. Soria JC, Brisgand D, Le Chevalier T: Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 12:1667-1670, 2001
42. Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 122:1037-1057, 2002